30 completed, 3 unknown, 1 active not recruiting, 1 recruiting. 37 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 37 | Completed 30, Unknown 3, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 8 | Completed 6, Unknown 2 |
Follow Rabeprazole: new trials by email Literature Review of Rabeprazole trials Research Report on Rabeprazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Anaprazole for Treating Reflux Esophagitis. Anaprazole + Rabeprazole placebo, Rabeprazole + Anaprazole placebo - Reflux Esophagitis (RE) | Phase 3 | Recruiting | Xuanzhu Biopharmaceutical Co., Ltd. | 500 | 2025-07-30 | 2025-09-29 |
| Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection Rifasutenizol capsules, Rabeprazole sodium enteric-coated tablets, Amoxicillin Capsules - H.Pylori Infection | Phase 3 | Completed | TenNor Therapeutics (Suzhou) Limited | 700 | 2023-05-18 | 2025-08-17 |
| A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers. Anaprazole Sodium, Rabeprazole, Rabeprazole Placebo - Duodenal Ulcer，DU | Phase 3 | Unknown | Sihuan Pharmaceutical Holdings Group Ltd. | 448 | 2020-01-20 | 2020-01-02 |
| This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients AL3810, carboplatin + etoposide, Placebo - Extensive-stage Small Cell Lung Cancer | Phase 2 / Phase 3 | Unknown | Haihe Biopharma Co., Ltd. | 313 | 2019-11-14 | 2020-02-05 |
| Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies 10d bismuth quadruple therapy, 14d hybrid therapy, 14D high-dose dual therapy - Helicobacter Pylori Infection | Phase 3 | Completed | Kaohsiung Veterans General Hospital. | 918 | 2018-09-03 | 2023-10-26 |
| Evaluation of Rebamipide and Rabeprazole Effect Associated or Not to Prevent Naproxen-induced Gastric Lesions 550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole., 550 mg naproxen + placebo + 20 mg rabeprazole, 550 mg naproxen + 300 mg rebamipide + placebo - Gastric Lesion | Phase 3 | Completed | Galeno Desenvolvimento de Pesquisas Clínicas | 32 | 2014-11-12 | 2018-09-05 |
| Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438) Vonoprazan, Esomeprazole, Rabeprazole sodium - Healthy Volunteers | Phase 3 | Completed | Takeda | 20 | 2014-01-01 | 2016-10-17 |
| A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients Rabeprazole - Gastroesophageal Reflux Disease | Phase 3 | Completed | Eisai Co., Ltd. | 517 | 2013-09-01 | 2023-06-22 |
| Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux. Rabeprazole 20mg bid, Rabeprazole 20mg qd - Esophageal Disease | Phase 3 | Completed | Seoul National University Hospital | 73 | 2012-10-10 | 2019-06-28 |
| Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study) Rabeprazole - Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin | Phase 2 / Phase 3 | Completed | Eisai Co., Ltd. | 405 | 2011-12-01 | 2015-12-21 |
| Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD rabeprazole, standard dose rabeprazole - Gastroesophageal Reflux Disease | Phase 3 | Withdrawn | Inje University | 2011-08-01 | 2012-01-18 | |
| Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study) E3810, Teprenone - Gastric or Duodenal Ulcers Caused by Low-dose Aspirin | Phase 2 / Phase 3 | Completed | Eisai Co., Ltd. | 472 | 2011-07-01 | 2014-11-26 |
| ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA Rabeprazole, Famotidine - Upper Gastrointestinal Bleeding | Phase 3 | Completed | Chinese University of Hong Kong | 264 | 2011-01-01 | 2017-04-21 |
| Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD) Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg, Placebo - Gastroesophageal Reflux | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 344 | 2009-11-01 | 2013-05-22 |
| A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury Rabeprazole, Rabeprazole Placebo - Osteoarthritis, Arthritis, Rheumatoid | Phase 3 | Completed | Chinese University of Hong Kong | 112 | 2009-05-01 | 2015-08-24 |
| Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment Transoral Incisionless Fundoplication, Proton Pump Inhibitors; active control - Gastroesophageal Reflux Disease (GERD) | Phase 3 | Terminated | University of Pittsburgh | 60 | 2009-03-01 | 2018-03-30 |
| A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients rabeprazole - Gastroesophageal Reflux Disease (GERD) | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 127 | 2009-01-01 | 2013-01-24 |
| Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD) rabeprazole sodium, Placebo - Symptomatic Gastroesophageal Reflux Disease (sGERD) | Phase 3 | Completed | Eisai Inc. | 305 | 2009-01-01 | 2016-02-02 |
| Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis E3810 - Refractory Reflux Esophagitis | Phase 2 / Phase 3 | Completed | Eisai Co., Ltd. | 337 | 2008-10-01 | 2012-04-18 |
| Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) Rabeprazole ER, Ranitidine - Gastroesophageal Reflux Disease (GERD) | Phase 3 | Completed | Eisai Inc. | 240 | 2008-08-31 | 2022-04-25 |
Showing 20 of 37. Sign in to see all of them.
Gastroesophageal Reflux (17) · Heartburn (6) · Duodenal Ulcer (4) · Stomach Ulcer (3) · Disease (2) · Esophagitis, Peptic (2) · Arthritis (1) · Arthritis, Rheumatoid (1) · Asthma (1) · Atrophy (1) · Dyspepsia (1) · Esophageal Diseases (1) · Esophagitis (1) · Gastritis (1) · Gastrointestinal Hemorrhage (1)
Eisai Inc. (9) · Eisai Co., Ltd. (5) · Chinese University of Hong Kong (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Associated Scientists to Help Minimize Allergies (1) · Galeno Desenvolvimento de Pesquisas Clínicas (1) · Haihe Biopharma Co., Ltd. (1) · Hamamatsu University (1) · Inje University (1) · Janssen Pharmaceutica N.V., Belgium (1) · Janssen-Ortho Inc., Canada (1) · Kaohsiung Veterans General Hospital. (1) · Livzon Pharmaceutical Group Inc. (1) · National Cancer Center, Korea (1) · Seoul National University Hospital (1)
United States (12) · Japan (10) · China (4) · Australia (3) · Bulgaria (3) · Hungary (3) · South Korea (3) · Argentina (2) · Canada (2) · Chile (2) · Croatia (2) · Estonia (2) · France (2) · Germany (2) · India (2)
Nobuyuki Sugisaki (4) · Yufang Lu (3) · Guillermo Rossiter, MD (2) · Yufang Lu, MD, PhD (2) · Blair A Jobe, MD (1) · Dong Ho Lee, MD, PhD (1) · Eun Hee Seo, M.D (1) · Francis K Chan, MD (1) · Francis KL Chan, MD (1) · Gilberto De Nucci, Doctor (1) · Guillermo Rossiter, M.D. (1) · Il Ju Choi, MD, PhD (1)
PMID 21114792, PMID 38910891, PMID 15233698, PMID 17721405, PMID 23689261, PMID 23863328, PMID 24121146, PMID 26628445, PMID 27641510, PMID 29188387, PMID 29562147, PMID 32811427, PMID 36580650, PMID 36940437, PMID 40945526